Residency · Residency · Radiation Oncology

Bladder Cancer: Trimodality Bladder Preservation

Introduction

Radical cystectomy with urinary diversion has long been considered the standard treatment for muscle-invasive bladder cancer (MIBC). However, trimodality therapy (TMT), which combines maximal transurethral resection of bladder tumor (TURBT), concurrent chemotherapy, and radiation therapy, provides a bladder-preserving alternative that achieves comparable oncologic outcomes in carefully selected patients. This approach allows patients to retain their native bladder function and avoid the significant morbidity associated with urinary diversion.

Patient Selection

Ideal candidates for TMT typically present with a unifocal tumor, meaning a single lesion is preferred, and the tumor size is less than 5 to 7 centimeters. A visibly complete TURBT, where no residual palpable or visible tumor remains, is essential. Patients should not have extensive carcinoma in situ (CIS), although focal CIS is acceptable. The absence of hydronephrosis is important, as its presence often indicates locally advanced disease and correlates with poorer outcomes. Candidates should have adequate bladder capacity and function, characterized by a compliant bladder without significant irritative symptoms. Clinically, patients with stage T2 to T3a disease are generally suitable, while those with T4 disease are usually not ideal candidates.

Relative contraindications include diffuse CIS throughout the bladder, multifocal tumors, incomplete TURBT with significant residual disease, poor baseline bladder function, and tumors involving the bladder neck or prostatic urethra, which are considered relative rather than absolute contraindications.

Trimodality Therapy Protocol

The first step in TMT is maximal TURBT, which is the most critical component. The goal is to achieve a visibly complete resection of all tumor tissue, as complete TURBT is the strongest predictor of successful outcomes with TMT. If the initial resection is incomplete, a repeat TURBT may be performed.

Following TURBT, concurrent chemoradiation is administered. Radiation targets the bladder and pelvic lymph nodes, while radiosensitizing chemotherapy is given simultaneously to enhance the effectiveness of radiation.

After the initial phase of chemoradiation, typically after delivering 40 Gy, a cystoscopic re-evaluation is performed. If a complete response (CR) is observed, the patient proceeds with consolidation chemoradiation to reach the full radiation dose. If the response is incomplete, salvage cystectomy is considered.

Radiation Technique

Radiation therapy is delivered in two phases. Phase 1 involves treating the whole bladder plus regional pelvic lymph nodes to a dose of 40 to 45 Gy. Phase 2, or consolidation, consists of a bladder boost—either the whole bladder or a partial bladder with a tumor bed boost—bringing the total dose to 64 to 65 Gy. The pelvic nodal clinical target volume (CTV) includes the obturator, internal iliac, external iliac, and presacral nodes.

Standard fractionation is used, with 1.8 to 2.0 Gy per fraction, totaling 64 to 65 Gy to the bladder and tumor bed over approximately 6.5 weeks. Because bladder volume can vary significantly with filling, a consistent bladder filling protocol is essential to ensure accurate targeting. Image-guided radiation therapy (IGRT) with daily cone-beam CT is strongly recommended to account for anatomical changes. Adaptive planning may be employed to adjust for bladder volume variations during treatment. Prone positioning can help reduce the radiation dose to the small bowel.

Concurrent Chemotherapy Regimens

Several chemotherapy regimens are preferred for concurrent use with radiation. The BC2001 trial regimen of 5-fluorouracil (5-FU) combined with mitomycin C is widely used. Cisplatin at 40 mg/m² weekly is the most common regimen in North America. Low-dose gemcitabine administered twice weekly at 27 mg/m² and the combination of 5-FU with cisplatin, as used in the Massachusetts General Hospital protocol, are also options.

The BC2001 trial demonstrated that adding concurrent 5-FU and mitomycin C to radiation improved locoregional disease-free survival without increasing late toxicity.

Outcomes

Oncologic outcomes following TMT are encouraging. The complete response rate after induction chemoradiation ranges from 70 to 80%. Five-year overall survival rates are approximately 50 to 60%, which is comparable to outcomes reported for radical cystectomy in retrospective studies. Five-year disease-specific survival ranges from 60 to 70%, and the intact bladder preservation rate at five years is between 70 and 80%.

Functionally, about 75% of long-term survivors maintain a well-functioning native bladder. Quality of life studies consistently show advantages in body image, sexual function, and social functioning when compared with patients who undergo cystectomy.

Patterns of failure include muscle-invasive local recurrence in 15 to 25% of patients, which is typically managed with salvage cystectomy. Non-muscle-invasive recurrence occurs in 20 to 30% and is generally treated with intravesical therapy. Distant metastases develop in 25 to 35% of cases.

Salvage Cystectomy

Salvage cystectomy is required in approximately 20 to 30% of patients undergoing TMT. Indications include incomplete response at the mid-treatment cystoscopic evaluation and muscle-invasive local recurrence. Although salvage cystectomy after radiation is technically more challenging, it is feasible with acceptable complication rates when performed at experienced centers. However, complication rates tend to be higher than those seen with primary cystectomy.

Key Trials and Evidence

Several key trials have shaped the current understanding of TMT. The BC2001 trial showed that adding chemotherapy (5-FU and mitomycin C) to radiation improved locoregional disease-free survival. The RTOG 0233 trial compared cisplatin alone, cisplatin with paclitaxel, and 5-FU with cisplatin, finding similar complete response rates across all arms. The Massachusetts General Hospital series reported a 75% intact bladder rate at five years using various protocols. The BCON trial demonstrated that radiosensitization with carbogen and nicotinamide improved local control when added to radiation.

Key Clinical Pearls

Complete TURBT stands out as the single most important factor predicting success with trimodality bladder preservation. Careful patient selection is crucial; ideal candidates have unifocal T2 tumors that are completely resected and lack diffuse CIS. The mid-treatment cystoscopic evaluation, typically performed at 40 Gy, guides whether to continue with consolidation chemoradiation or proceed to salvage cystectomy. Importantly, five-year overall survival with TMT is comparable to that of radical cystectomy in appropriately selected patients, with about 75% of survivors maintaining a functional bladder.

References

1. James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477-1488.
2. Giacalone NJ, Shipley WU, Clayman RH, et al. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience. Eur Urol. 2017;71(6):952-960.
3. Mak RH, Hunt D, Shipley WU, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols. J Clin Oncol. 2014;32(34):3801-3809.
4. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 3.2025.

Read this lecture as Markdown